EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Franck Morschhauser iD, Gilles Salles iD, Laurie H Sehn iD, Alex F Herrera iD, Jonathan W Friedberg, Marek Trněný iD, Georg Lenz, Jeff P Sharman iD, Charles Herbaux iD, John M Burke, Matthew Matasar iD, Graham P Collins iD und 25 weitere

Journal of Clinical Oncology · 10.12.2025 · 43 (35) · 3698-3705

DOI: 10.1200/jco-25-00925 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.12.2025. Verfasst von Franck Morschhauser und 36 weiteren Autor:innen. Beteiligte Einrichtung: University of Lille, Lille, France. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492 ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsHumansCyclophosphamideDoxorubicinVincristinePrednisoneRituximabMiddle AgedMaleFemaleAgedAdultProgression-Free SurvivalAntibodies, Monoclonal, HumanizedAged, 80 and overYoung AdultAntibodies, MonoclonalImmunoconjugates

Substanzen

CyclophosphamideDoxorubicinVincristinePrednisoneRituximabR-CHOP protocolAntibodies, Monoclonal, Humanizedpolatuzumab vedotinAntibodies, MonoclonalImmunoconjugates

Autor:innen und Institutionen

  • University of Lille, Lille, France.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada.
  • City of Hope, Duarte, CA.
  • Wilmot Cancer Institute, University of Rochester, Rochester, NY.
  • Charles University, Prague, Czech Republic.

ORCID-Profile: Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Marek Trněný, Jeff P Sharman, Charles Herbaux, Matthew Matasar, Graham P Collins, Lucie Oberic, Shinya Rai, Koji Izutsu, Richard Greil, Juan M Bergua-Burgués, Greg Hapgood, Pau Abrisqueta, Matthew Sugidono, Connie Lee Batlevi, Hervé Tilly, Christopher R Flowers

Förderung

  • NCI NIH HHS

Zitieren

APA

Morschhauser, F., Salles, G., Sehn, L. H., Herrera, A. F., Friedberg, J. W., Trněný, M., Lenz, G., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Collins, G. P., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y., Pinto, A., Rai, S., …, & Flowers, C. R. (2025). Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 43(35), 3698-3705. https://doi.org/10.1200/jco-25-00925

Vancouver

Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, et al. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 2025;43(35):3698-3705. doi:10.1200/jco-25-00925

BibTeX
@article{Morschhauser2025,
  author = {Morschhauser, Franck and Salles, Gilles and Sehn, Laurie H and Herrera, Alex F and Friedberg, Jonathan W and Trněný, Marek and Lenz, Georg and Sharman, Jeff P and Herbaux, Charles and Burke, John M and Matasar, Matthew and Collins, Graham P and Mehta-Shah, Neha and Oberic, Lucie and Chauchet, Adrien and Jurczak, Wojciech and Song, Yuqin and Pinto, Antonio and Rai, Shinya and Izutsu, Koji and Greil, Richard and Mykhalska, Larysa and Bergua-Burgués, Juan M and Cheung, Matthew C and Shin, Ho-Jin and Hapgood, Greg and Munhoz, Eduardo and Abrisqueta, Pau and Gau, Jyh-Pyng and Jiang, Yanwen and McCall, Bruce and Chohan, Saibah and Sugidono, Matthew and Yan, Mark and Batlevi, Connie Lee and Tilly, Hervé and Flowers, Christopher R},
  title = {Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {35},
  pages = {3698--3705},
  doi = {10.1200/jco-25-00925}
}
Kostenlos starten →